CLINICAL TRIALS PROFILE FOR REZULIN
✉ Email this page to a colleague
All Clinical Trials for REZULIN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00003058 ↗ | Troglitazone in Treating Patients With Liposarcoma | Completed | National Cancer Institute (NCI) | Phase 2 | 1997-06-01 | Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype. |
NCT00003058 ↗ | Troglitazone in Treating Patients With Liposarcoma | Completed | Dana-Farber Cancer Institute | Phase 2 | 1997-06-01 | Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype. |
NCT01068860 ↗ | To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies | Completed | Novartis | Phase 2 | 2010-02-01 | This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes therapies. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for REZULIN
Condition Name
Clinical Trial Locations for REZULIN
Trials by Country
Clinical Trial Progress for REZULIN
Clinical Trial Phase
Clinical Trial Sponsors for REZULIN
Sponsor Name